RCS - Belluscura PLC - Belluscura Expands its Patent Portfolio

BelluscuraAnnouncement

19/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220519:nRSS0253Ma&default-theme=true

RNS Number : 0253M  Belluscura PLC  19 May 2022

Belluscura PLC

("Belluscura" or the "Company")

 

Belluscura Expands its Oxygen Enrichment Patent Portfolio

 

Three New Patents Issue related to Extracorporeal membrane oxygenation (ECMO),
Continuous Positive Airway Pressure (CPAP) and Replaceable Molecular Sieve
Technology

 

LONDON, U.K. AND PLANO, TX, U.S. (19 May 2022). Belluscura plc (AIM: BELL), a
leading medical device developer focused on lightweight and portable oxygen
enrichment technology, announces that three additional US patents have
recently issued, increasing the number of issued and pending patent
applications the Company owns or exclusively licenses to thirty.

 

The technology covered by the patents, includes:

 

·    Extracorporeal membrane oxygenation (ECMO) innovations for when
people who are very ill with conditions of the heart and lungs, or who are
waiting for or recovering from a heart transplant, require a portable
artificial lung;

·    Continuous Positive Airway Pressure (CPAP) innovations, a type of
non-invasive ventilation (NIV) or breathing support, and;

·    Consumer replaceable molecular sieve technology, used to remove
Nitrogen from ordinary air to produce medical grade supplemental oxygen.

 

Robert Rauker, CEO of Belluscura plc, said: "Our pioneering engineering team
continues to develop next generation oxygen enrichment technology along with
our research partner, Separation Design Group. We see significant expanding
future opportunities in the supplemental oxygen field."

 

 

For further information please contact:

 

 Belluscura plc                                    www.belluscura.com (http://www.belluscura.com)
 Robert Rauker, Chief Executive Officer            via Walbrook PR
 Anthony Dyer, Chief Financial Officer

 SPARK Advisory Partners Limited (NOMAD)           Tel: +44 (0)20 3368 3550
 Neil Baldwin

 Dowgate Capital Limited (Broker)                  Tel: +44 (0)20 3903 7715
 James Serjeant / Nicholas Chambers

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Belluscura plc (www.belluscura.com (http://www.belluscura.com) )

Belluscura is a UK medical device company focused on developing oxygen
enrichment technology spanning broad industries and therapies. Our innovative
oxygen technologies are designed with a global purpose: to create improved
health and economic outcomes for the patients, healthcare providers and
insurance organisations.

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFMESAEESEDI